Literature DB >> 10702797

Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis.

D L Hadsell1, K L Murphy, S G Bonnette, N Reece, R Laucirica, J M Rosen.   

Abstract

Mammary tumorigenesis was analysed in transgenic mice which overexpress des(1-3)hIGF-I (WAP-DES) and/or a mutant form of p53 (p53172R-H). Nonlactating, multiparous WAP-DES mice exhibited hyperplastic lesions termed mammary interepithelial neoplasia (MIN) which constitutively expressed WAP-DES. By 23 months of age, 53% of the WAP-DES mice developed mammary adenocarcinomas. A 75% reduction in both apoptosis and proliferation was observed in the normal mammary glands of WAP-DES mice. Mammary tumor incidence in WAP-DES/p53 bitransgenic mice was similar to that of WAP-DES and 2 - 3-fold greater than that of nontransgenic and p53172R-H females. Tumor latency, however, was reduced by 8 months in bitransgenic mice as compared to mice of the other three genotypes. Aneuploidy was frequently observed in tumors from bitransgenic and p53172R-H mice, but not from mice expressing only the WAP-DES transgene. Expression of IGFBP3 was elevated in tumors from WAP-DES, but not bitransgenic mice, indicating an alteration in the p53/IGF-I axis. These studies indicate that overexpression of des(1-3)hIGF-I increases the frequency of MIN and stochastic mammary tumors and that the appearance of tumors displaying genomic instability is accelerated by mutant p53172R-H. Oncogene (2000) 19, 889 - 898.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10702797     DOI: 10.1038/sj.onc.1203386

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  21 in total

1.  Expression of IGF1R in normal breast tissue and subsequent risk of breast cancer.

Authors:  Rulla M Tamimi; Graham A Colditz; Yihong Wang; Laura C Collins; Rong Hu; Bernard Rosner; Hanna Y Irie; James L Connolly; Stuart J Schnitt
Journal:  Breast Cancer Res Treat       Date:  2011-01-01       Impact factor: 4.872

Review 2.  Inhibitors of insulin-like growth factor signaling: a therapeutic approach for breast cancer.

Authors:  Deepali Sachdev; Douglas Yee
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-01       Impact factor: 2.673

3.  Mammary tumorigenesis and metastasis caused by overexpression of insulin receptor substrate 1 (IRS-1) or IRS-2.

Authors:  Robert K Dearth; Xiaojiang Cui; Hyun-Jung Kim; Isere Kuiatse; Nicole A Lawrence; Xiaomei Zhang; Jana Divisova; Ora L Britton; Syed Mohsin; D Craig Allred; Darryl L Hadsell; Adrian V Lee
Journal:  Mol Cell Biol       Date:  2006-10-09       Impact factor: 4.272

Review 4.  Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions.

Authors:  David L Kleinberg; Teresa L Wood; Priscilla A Furth; Adrian V Lee
Journal:  Endocr Rev       Date:  2008-12-15       Impact factor: 19.871

Review 5.  Acromegaly: re-thinking the cancer risk.

Authors:  Siobhan Loeper; Shereen Ezzat
Journal:  Rev Endocr Metab Disord       Date:  2008-03       Impact factor: 6.514

6.  PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancer.

Authors:  A Belfiore; M Genua; R Malaguarnera
Journal:  PPAR Res       Date:  2009-07-07       Impact factor: 4.964

7.  Paracrine overexpression of insulin-like growth factor-1 enhances mammary tumorigenesis in vivo.

Authors:  Krisztina Kovács de Ostrovich; Isabel Lambertz; Jennifer K L Colby; Jie Tian; Joyce E Rundhaug; Dennis Johnston; Claudio J Conti; John DiGiovanni; Robin Fuchs-Young
Journal:  Am J Pathol       Date:  2008-08-07       Impact factor: 4.307

Review 8.  The role of endocrine insulin-like growth factor-I and insulin in breast cancer.

Authors:  Danielle Lann; Derek LeRoith
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-11-22       Impact factor: 2.673

9.  A novel unidirectional cross-talk from the insulin-like growth factor-I receptor to leptin receptor in human breast cancer cells.

Authors:  Tuba Ozbay; Rita Nahta
Journal:  Mol Cancer Res       Date:  2008-05-30       Impact factor: 5.852

Review 10.  Insulin resistance and hyperinsulinaemia in the development and progression of cancer.

Authors:  Ian F Godsland
Journal:  Clin Sci (Lond)       Date:  2009-11-23       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.